Harnessing the predictive power of preclinical models for oncology drug development

Double-slit photoelectron interference in strong-field ionization of the neon dimer

Kunitski, M., Eicke, N., Huber, P., Köhler, J., Zeller, S., Voigtsberger, J., Schlott, N., Henrichs, K., Sann, H., Trinter, F., et al. (2019) · Institutional Repository of Leibniz Universität Hannover (Leibniz Universität Hannover) · doi:10.15488/5174 · Cited by 8,378 · see citing works

Double-slit photoelectron interference in strong-field ionization of the neon dimer

Kunitski, M., Eicke, N., Huber, P., Köhler, J., Zeller, S., Voigtsberger, J., Schlott, N., Henrichs, K., Sann, H., Trinter, F., et al. (2019) · Nature Communications · doi:10.1038/s41467-018-07882-8 · Cited by 8,162 · see citing works

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

Chapman, P. B., Hauschild, A., Robert, C., Haanen, J. B., Ascierto, P., Larkin, J., Dummer, R., Garbe, C., Testori, A., Maio, M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103782 · Cited by 7,720 · see citing works

Osimertinib in Untreated <i>EGFR</i> -Mutated Advanced Non–Small-Cell Lung Cancer

Soria, J.-C., Ohe, Y., Vansteenkiste, J., Reungwetwattana, T., Chewaskulyong, B., Lee, K. H., Dechaphunkul, A., Imamura, F., Nogami, N., Kurata, T., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1713137 · Cited by 5,508 · see citing works

Cancer drug resistance: an evolving paradigm

Holohan, C., Van Schaeybroeck, S., Longley, D. B., & Johnston, P. G. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3599 · Cited by 4,681 · see citing works

EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib

Pao, W., Miller, V., Zakowski, M., Doherty, J., Politi, K., Sarkaria, I., Singh, B., Heelan, R., Rusch, V., Fulton, L., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0405220101 · Cited by 4,338 · see citing works

Genomics of Drug Sensitivity in Cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells

Yang, W., Soares, J., Greninger, P., Edelman, E. J., Lightfoot, H., Forbes, S., Bindal, N., Beare, D., Smith, J. A., Thompson, I. R., et al. (2012) · Nucleic Acids Research · doi:10.1093/nar/gks1111 · Cited by 4,051 · see citing works

Inhibition of Mutated, Activated BRAF in Metastatic Melanoma

Flaherty, K. T., Puzanov, I. J., Kim, K. B., Ribas, A., McArthur, G. A., Sosman, J. A., O'Dwyer, P. J., Lee, R. J., Grippo, J. F., Nolop, K. B., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1002011 · Cited by 3,542 · see citing works

Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain

Pao, W., Miller, V. A., Politi, K. A., Riely, G. J., Somwar, R., Zakowski, M. F., Kris, M. G., & Varmus, H. (2005) · PLoS Medicine · doi:10.1371/journal.pmed.0020073 · Cited by 3,527 · see citing works

Defining a Cancer Dependency Map

Tsherniak, A., Vazquez, F., Montgomery, P. G., Weir, B. A., Kryukov, G., Cowley, G. S., Gill, S., Harrington, W. F., Pantel, S., Krill-Burger, J. M., et al. (2017) · Cell · doi:10.1016/j.cell.2017.06.010 · Cited by 3,276 · see citing works

Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer

Olive, K. P., Jacobetz, M. A., Davidson, C. J., Gopinathan, A., McIntyre, D., Honess, D., Madhu, B., Goldgraben, M. A., Caldwell, M. E., Allard, D., et al. (2009) · Science · doi:10.1126/science.1171362 · Cited by 3,170 · see citing works

Efficacy of Larotrectinib in <i>TRK</i> Fusion–Positive Cancers in Adults and Children

Drilon, A., Laetsch, T. W., Kummar, S., DuBois, S. G., Lassen, U. N., Demetri, G. D., Nathenson, M., Doebele, R. C., Farago, A. F., Pappo, A. S., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1714448 · Cited by 2,824 · see citing works

Mechanism of Activation of the RAF-ERK Signaling Pathway by Oncogenic Mutations of B-RAF

Wan, P., Garnett, M. J., Roe, S. M., Lee, S., Niculescu‐Duvaz, D., Good, V. M., Cancer Genome Project, Jones, C. M., Marshall, C. J., Springer, C. J., et al. (2004) · Cell · doi:10.1016/s0092-8674(04)00215-6 · Cited by 2,800 · see citing works

Systematic identification of genomic markers of drug sensitivity in cancer cells

Garnett, M. J., Edelman, E. J., Heidorn, S. J., Greenman, C. D., Dastur, A., Lau, K. W., Greninger, P., Thompson, I. R., Luo, X., Soares, J., et al. (2012) · Nature · doi:10.1038/nature11005 · Cited by 2,456 · see citing works

Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation

Nazarian, R., Shi, H., Wang, Q., Kong, X., Koya, R. C., Lee, H., Chen, Z., Lee, M., Attar, N., Sazegar, H., et al. (2010) · Nature · doi:10.1038/nature09626 · Cited by 2,198 · see citing works

Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib

Sosman, J. A., Kim, K. B., Schuchter, L., Gonzalez, R., Pavlick, A. C., Weber, J. S., McArthur, G. A., Hutson, T. E., Moschos, S. J., Flaherty, K. T., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1112302 · Cited by 2,156 · see citing works

Patient-derived organoids model treatment response of metastatic gastrointestinal cancers

Vlachogiannis, G., Hedayat, S., Vatsiou, A., Jamin, Y., Fernández-Mateos, J., Khan, K., Lampis, A., Eason, K., Huntingford, I., Burke, R., et al. (2018) · Science · doi:10.1126/science.aao2774 · Cited by 2,096 · see citing works

Stromal Elements Act to Restrain, Rather Than Support, Pancreatic Ductal Adenocarcinoma

Rhim, A. D., Oberstein, P. E., Thomas, D. H., Mirek, E. T., Palermo, C. F., Sastra, S. A., Dekleva, E. N., Saunders, T., Becerra, C. P., Tattersall, I. W., et al. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.04.021 · Cited by 2,085 · see citing works

Combined Vemurafenib and Cobimetinib in BRAF -Mutated Melanoma

Larkin, J., Ascierto, P. A., Dréno, B., Atkinson, V. G., Liszkay, G., Maio, M., Mandalà, M., Демидов, Л. В., Stroyakovskiy, D., Thomas, L., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1408868 · Cited by 2,061 · see citing works

Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR

Prahallad, A., Sun, C., Huang, S., Di Nicolantonio, F., Salazar, R., Zecchin, D., Beijersbergen, R. L., Bardelli, A., & Bernards, R. (2012) · Nature · doi:10.1038/nature10868 · Cited by 2,051 · see citing works

Diagnosing the decline in pharmaceutical R&amp;D efficiency

Scannell, J. W., Blanckley, A., Boldon, H., & Warrington, B. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3681 · Cited by 1,981 · see citing works

RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF

Poulikakos, P. I., Zhang, C., Bollag, G. E., Shokat, K. M., & Rosen, N. X. (2010) · Nature · doi:10.1038/nature08902 · Cited by 1,818 · see citing works

Vemurafenib in Multiple Nonmelanoma Cancers with <i>BRAF</i> V600 Mutations

Hyman, D. M., Puzanov, I., Subbiah, V., Faris, J. E., Chau, I., Blay, J.-Y., Wolf, J., Raje, N. S., Diamond, E. L., Hollebecque, A., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1502309 · Cited by 1,764 · see citing works

Patient-Derived Xenograft Models: An Emerging Platform for Translational Cancer Research

Hidalgo, M. M., Amant, F. C., Biankin, A. V., Budínská, E., Byrne, A. T., Caldas, C., Clarke, R. B., de Jong, S., Jonkers, J., Mælandsmo, G. M., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-0001 · Cited by 1,759 · see citing works

Gefitinib in Combination With Gemcitabine and Cisplatin in Advanced Non–Small-Cell Lung Cancer: A Phase III Trial—INTACT 1

Giaccone, G., Herbst, R. S., Manegold, C., Scagliotti, G. V., Rosell, R., Miller, V. A., Natale, R. B., Schiller, J. H., von Pawel, J., Pluzanska, A., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.08.001 · Cited by 1,712 · see citing works

Gefitinib in Combination With Paclitaxel and Carboplatin in Advanced Non–Small-Cell Lung Cancer: A Phase III Trial—INTACT 2

Herbst, R. S., Giaccone, G., Schiller, J. H., Natale, R. B., Miller, V. A., Manegold, C., Scagliotti, G. V., Rosell, R., Oliff, I. A., Reeves, J. A., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.07.215 · Cited by 1,703 · see citing works

RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth

Hatzivassiliou, G., Song, K. W., Yen, I., Brandhuber, B. J., Anderson, D. J., Alvarado, R., Ludlam, M. J. C., Stokoe, D., Gloor, S. L., Vigers, G. P. A., et al. (2010) · Nature · doi:10.1038/nature08833 · Cited by 1,614 · see citing works

Estimation of clinical trial success rates and related parameters

Wong, C. H., Siah, K. W., & Lo, A. W. (2019) · Biostatistics · doi:10.1093/biostatistics/kxx069 · Cited by 1,585 · see citing works

Organoid modeling of the tumor immune microenvironment

Neal, J. T., Li, X., Zhu, J., Giangarra, V., Grzeskowiak, C. L., Ju, J., Liu, I. H., Chiou, S.-H., Salahudeen, A. A., Smith, A. R., et al. (2018) · Cell · doi:10.1016/j.cell.2018.11.021 · Cited by 1,556 · see citing works

Adjuvant Dabrafenib plus Trametinib in Stage III BRAF -Mutated Melanoma

Long, G. V., Hauschild, A., Santinami, M., Atkinson, V. G., Mandalà, M., Chiarion‐Sileni, V., Larkin, J., Nyakas, M., Dutriaux, C., Haydon, A. M., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1708539 · Cited by 1,510 · see citing works

Human primary liver cancer–derived organoid cultures for disease modeling and drug screening

Broutier, L., Mastrogiovanni, G., Verstegen, M. M., Francies, H. E., Gavarró, L. M., Bradshaw, C. R., Allen, G. E., Arnes-Benito, R., Sidorova, O., Gaspersz, M. P., et al. (2017) · Nature Medicine · doi:10.1038/nm.4438 · Cited by 1,471 · see citing works

Kinase-Dead BRAF and Oncogenic RAS Cooperate to Drive Tumor Progression through CRAF

Heidorn, S. J., Milagre, C. S., Whittaker, S. R., Nourry, A., Niculescu‐Duvaz, I., Dhomen, N. S., Hussain, J., Reis-Filho, J. S., Springer, C. J., Pritchard, C. A., et al. (2010) · Cell · doi:10.1016/j.cell.2009.12.040 · Cited by 1,468 · see citing works

RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)

Poulikakos, P. I., Persaud, Y., Janakiraman, M., Kong, X., Ng, C., Moriceau, G., Shi, H., Atefi, M., Titz, B., Gabay, M. T., et al. (2011) · Nature · doi:10.1038/nature10662 · Cited by 1,454 · see citing works

Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer

Leonetti, A., Sharma, S., Minari, R., Perego, P., Giovannetti, E., & Tiseo, M. (2019) · British Journal of Cancer · doi:10.1038/s41416-019-0573-8 · Cited by 1,446 · see citing works

Evaluating cell lines as tumour models by comparison of genomic profiles

Domcke, S., Sinha, R., Levine, D. A., Sander, C., & Schultz, N. D. (2013) · Nature Communications · doi:10.1038/ncomms3126 · Cited by 1,426 · see citing works

High-throughput screening using patient-derived tumor xenografts to predict clinical trial drug response

Gao, H., Korn, J. M., Ferretti, S., Monahan, J. E., Wang, Y., Singh, M., Zhang, C., Schnell, C., Yang, G., Zhang, Y., et al. (2015) · Nature Medicine · doi:10.1038/nm.3954 · Cited by 1,393 · see citing works

Acquired Resistance to BRAF Inhibitors Mediated by a RAF Kinase Switch in Melanoma Can Be Overcome by Cotargeting MEK and IGF-1R/PI3K

Villanueva, J., Vultur, A., Lee, J. T., Somasundaram, R., Fukunaga‐Kalabis, M., Cipolla, A. K., Wubbenhorst, B. S., Xu, X., Gimotty, P. A., Kee, D., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.11.023 · Cited by 1,261 · see citing works

Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial

Wu, Y.-L., Cheng, Y., Zhou, X., Lee, K. H., Nakagawa, K., Niho, S., Tsuji, F., Linke, R., Rosell, R., Corral, J., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30608-3 · Cited by 1,216 · see citing works

RAS Mutations in Cutaneous Squamous-Cell Carcinomas in Patients Treated with BRAF Inhibitors

Su, F., Virós, A., Milagre, C. S., Trunzer, K., Bollag, G. E., Spleiss, O., Reis-Filho, J. S., Kong, X., Koya, R. C., Flaherty, K. T., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1105358 · Cited by 1,038 · see citing works

Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial

Dummer, R., Ascierto, P. A., Gogas, H. J., Arance, A. M., Mandalà, M., Liszkay, G., Garbe, C., Schadendorf, D., Krajsová, I., Gutzmer, R., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30142-6 · Cited by 1,034 · see citing works

EGFR-Mediated Reactivation of MAPK Signaling Contributes to Insensitivity of <i>BRAF</i> -Mutant Colorectal Cancers to RAF Inhibition with Vemurafenib

Corcoran, R. B., Ebi, H., Turke, A. B., Coffee, E. M., Nishino, M., Cogdill, A. P., Brown, R. D., Della Pelle, P., Dias-Santagata, D., Hung, K. E., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0341 · Cited by 1,022 · see citing works

Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial

Sartore-Bianchi, A., Trusolino, L., Martino, C., Bencardino, K., Lonardi, S., Bergamo, F., Zagonel, V., Leone, F., Depetris, I., Martinelli, E., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)00150-9 · Cited by 1,016 · see citing works

Tumor grafts derived from women with breast cancer authentically reflect tumor pathology, growth, metastasis and disease outcomes

DeRose, Y. S., Wang, G., Lin, Y.-C., Bernard, P. S., Buys, S. S., Ebbert, M., Factor, R. E., Matsen, C. B., Milash, B. A., Nelson, E. W., et al. (2011) · Nature Medicine · doi:10.1038/nm.2454 · Cited by 1,006 · see citing works

Dissecting Therapeutic Resistance to RAF Inhibition in Melanoma by Tumor Genomic Profiling

Wagle, N., Emery, C., Berger, M. F., Davis, M. J., Sawyer, A. M., Pochanard, P., Kehoe, S. M., Johannessen, C. M., MacConaill, L. E., Hahn, W. C., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.33.2312 · Cited by 996 · see citing works

Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition

Hata, A. N., Niederst, M. J., Archibald, H. L., Gomez-Caraballo, M., Siddiqui, F. M., Mulvey, H. E., Maruvka, Y. E., Ji, F., Bhang, H.-E. C., Krishnamurthy Radhakrishna, V., et al. (2016) · Nature Medicine · doi:10.1038/nm.4040 · Cited by 985 · see citing works

Acquired Resistance and Clonal Evolution in Melanoma during BRAF Inhibitor Therapy

Shi, H., Hugo, W., Kong, X., Hong, A., Koya, R. C., Moriceau, G., Chodon, T., Guo, R., Johnson, D. B., Dahlman, K. B., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0642 · Cited by 982 · see citing works

A molecularly annotated platform of patient-derived xenografts (“xenopatients”) identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer

Bertotti, A., Migliardi, G., Galimi, F., Sassi, F., Torti, D., Isella, C., Corà, D., Di Nicolantonio, F., Buscarino, M., Petti, C., et al. (2011) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0109 · Cited by 939 · see citing works

Cancer modeling meets human organoid technology

Tuveson, D., & Clevers, H. (2019) · Science · doi:10.1126/science.aaw6985 · Cited by 935 · see citing works

Genetic and transcriptional evolution alters cancer cell line drug response

Ben-David, U., Siranosian, B., Ha, G., Tang, H., Oren, Y., Hinohara, K., Strathdee, C. A., Dempster, J., Lyons, N. J., Burns, R., et al. (2018) · Nature · doi:10.1038/s41586-018-0409-3 · Cited by 931 · see citing works

Carcinogen-specific mutation and amplification of Ha-ras during mouse skin carcinogenesis

Quintanilla, M., Brown, K., Ramsden, M., & Balmain, A. (1986) · Nature · doi:10.1038/322078a0 · Cited by 860 · see citing works

A distinct role for Lgr5+ stem cells in primary and metastatic colon cancer

Melo, F. D. S. E., Kurtova, A. V., Harnoss, J. M., Kljavin, N. M., Hoeck, J. D., Hung, J., Anderson, J. E., Storm, E. E., Modrusan, Z. D., Koeppen, H., et al. (2017) · Nature · doi:10.1038/nature21713 · Cited by 782 · see citing works

The great escape: tumour cell plasticity in resistance to targeted therapy

Boumahdi, S., & de Sauvage, F. J. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0044-1 · Cited by 759 · see citing works

Patient-derived xenografts undergo mouse-specific tumor evolution

Ben-David, U., Ha, G., Tseng, Y.-Y., Greenwald, N. F., Oh, C., Shih, J., McFarland, J. M., Wong, B., Boehm, J. S., Beroukhim, R., et al. (2017) · Nature Genetics · doi:10.1038/ng.3967 · Cited by 716 · see citing works

Patient-derived models of acquired resistance can identify effective drug combinations for cancer

Crystal, A. S., Shaw, A. T., Sequist, L. V., Friboulet, L., Niederst, M. J., Lockerman, E. L., Frias, R. L., Gainor, J. F., Amzallag, A., Greninger, P., et al. (2014) · Science · doi:10.1126/science.1254721 · Cited by 708 · see citing works

Phase II Pilot Study of Vemurafenib in Patients With Metastatic <i>BRAF</i> -Mutated Colorectal Cancer

Kopetz, S., Desai, J., Chan, E., Hecht, J. R., O'Dwyer, P. J., Maru, D., Morris, V., Janku, F., Dasari, A., Chung, W., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.63.2497 · Cited by 697 · see citing works

Oncogenic Transformation by Inhibitor-Sensitive and -Resistant EGFR Mutants

Greulich, H., Chen, T.-H., Feng, W., Jänne, P. A., Alvarez, J. V., Zappaterra, M., Bulmer, S. E., Frank, D. A., Hahn, W. C., Sellers, W. R., et al. (2005) · PLoS Medicine · doi:10.1371/journal.pmed.0020313 · Cited by 677 · see citing works

Project DRIVE: a compendium of cancer dependencies and synthetic lethal relationships uncovered by large-scale, deep RNAi screening

McDonald, E. R., de Weck, A., Schlabach, M. R., Billy, E., Mavrakis, K. J., Hoffman, G. R., Belur, D., Castelletti, D., Frias, E., Gampa, K., et al. (2017) · Cell · doi:10.1016/j.cell.2017.07.005 · Cited by 658 · see citing works

MEK1 mutations confer resistance to MEK and B-RAF inhibition

Emery, C. M., Vijayendran, K. G., Zipser, M. C., Sawyer, A. M., Niu, L., Kim, J. J., Hatton, C., Chopra, R., Oberholzer, P. A., Karpova, M. B., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0905833106 · Cited by 633 · see citing works

Oncogenic Braf Induces Melanocyte Senescence and Melanoma in Mice

Dhomen, N. S., Reis-Filho, J. S., Dias, S. D. R., Hayward, R., Savage, K., Delmas, V., Larue, L., Pritchard, C. A., & Marais, R. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.02.022 · Cited by 595 · see citing works

Combined BRAF, EGFR, and MEK Inhibition in Patients with <i>BRAF</i> V600E-Mutant Colorectal Cancer

Corcoran, R. B., André, T., Atreya, C. E., Schellens, J. H. M., Yoshino, T., Bendell, J. C., Hollebecque, A., McRee, A. J., Siena, S., Middleton, G., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-1226 · Cited by 592 · see citing works

Randomized phase Ib/II study of gemcitabine plus placebo or vismodegib, a hedgehog pathway inhibitor, in patients with metastatic pancreatic cancer

Catenacci, D. V. T., Junttila, M. R., Karrison, T., Bahary, N., Horiba, M. N., Nattam, S. R., Marsh, R., Wallace, J., Kozloff, M., Rajdev, L., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.62.8719 · Cited by 561 · see citing works

Correction: Corrigendum: ER-localized auxin transporter PIN8 regulates auxin homoeostasis and male gametophyte development in Arabidopsis

Ding, Z., Wang, B., Moreno, I., Dupľáková, N., Simon, S., Carraro, N., Reemmer, J., Pěnčík, A., Chen, X., Tejos, R., et al. (2013) · Nature Communications · doi:10.1038/ncomms2452 · Cited by 555 · see citing works

Genetically engineered mouse models in oncology research and cancer medicine

Kersten, K., de Visser, K. E., van Miltenburg, M. H., & Jonkers, J. (2017) · EMBO Molecular Medicine · doi:10.15252/emmm.201606857 · Cited by 502 · see citing works

Impact of Precision Medicine in Diverse Cancers: A Meta-Analysis of Phase II Clinical Trials

Schwaederle, M. C., Zhao, M. M., Lee, J. J., Eggermont, A. M. M., Schilsky, R. L., Mendelsohn, J. M., Lazar, V., & Kurzrock, R. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.61.5997 · Cited by 495 · see citing works

Lung adenocarcinomas induced in mice by mutant EGF receptors foundin human lung cancers respondto a tyrosine kinase inhibitor orto down-regulation of the receptors

Politi, K., Zakowski, M. F., Fan, P.-D., Schonfeld, E. A., Pao, W., & Varmus, H. E. (2006) · Genes &amp; Development · doi:10.1101/gad.1417406 · Cited by 478 · see citing works

A new mouse model to explore the initiation, progression, and therapy of BRAF V600E -induced lung tumorsPreprint

Dankort, D. L., Filenova, E., Collado, M., Serrano, M., Jones, K. D., & McMahon, M. (2007) · Genes & Development · doi:10.1101/gad.1516407 · Cited by 476 · see citing works

The impact of human EGFR kinase domain mutations on lung tumorigenesis and in vivo sensitivity to EGFR-targeted therapies

Ji, H., Li, D., Chen, L., Shimamura, T., Kobayashi, S., McNamara, K., Mahmood, U., Mitchell, A., Sun, Y., Al-Hashem, R., et al. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.04.022 · Cited by 462 · see citing works

Tumor Analyses Reveal Squamous Transformation and Off-Target Alterations As Early Resistance Mechanisms to First-line Osimertinib in <i>EGFR</i> -Mutant Lung Cancer

Schoenfeld, A. J., Chan, J. M., Kubota, D., Sato, H., Rizvi, H., Daneshbod, Y., Chang, J. C., Paik, P. K., Offin, M., Arcila, M. E., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-3563 · Cited by 411 · see citing works

Development of primary human pancreatic cancer organoids, matched stromal and immune cells and 3D tumor microenvironment models

Tsai, S., McOlash, L., Palen, K., Johnson, B., Duris, C., Yang, Q., Dwinell, M. B., Hunt, B., Evans, D. B., Gershan, J., et al. (2018) · BMC Cancer · doi:10.1186/s12885-018-4238-4 · Cited by 400 · see citing works

RAS Mutations Are Associated With the Development of Cutaneous Squamous Cell Tumors in Patients Treated With RAF Inhibitors

Oberholzer, P. A., Kee, D., Dziunycz, P., Sucker, A., Kamsu-Kom, N., Jones, R. T., Roden, C., Chalk, C. J., Ardlie, K., Palescandolo, E., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.36.7680 · Cited by 386 · see citing works

Estimation of the Percentage of US Patients With Cancer Who Benefit From Genome-Driven Oncology

Marquart, J. P., Chen, E. Y.-S., & Prasad, V. K. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2018.1660 · Cited by 378 · see citing works

Resistance to BRAF-targeted therapy in melanoma

Sullivan, R. J., & Flaherty, K. T. (2013) · European Journal of Cancer · doi:10.1016/j.ejca.2012.11.019 · Cited by 373 · see citing works

Examining the utility of patient-derived xenograft mouse models

Aparicio, S. A. J. R., Hidalgo, M. M., & Kung, A. L. (2015) · Nature reviews. Cancer · doi:10.1038/nrc3944 · Cited by 345 · see citing works

Tunable-Combinatorial Mechanisms of Acquired Resistance Limit the Efficacy of BRAF/MEK Cotargeting but Result in Melanoma Drug Addiction

Moriceau, G., Hugo, W., Hong, A., Shi, H., Kong, X., Yu, C. C., Koya, R. C., Samatar, A. A., Khanlou, N., Braun, J. G., et al. (2015) · Cancer Cell · doi:10.1016/j.ccell.2014.11.018 · Cited by 345 · see citing works

Afatinib: First Global Approval

Dungo, R. T., & Keating, G. M. (2013) · Drugs · doi:10.1007/s40265-013-0111-6 · Cited by 340 · see citing works

The mutational landscapes of genetic and chemical models of Kras-driven lung cancer

Westcott, P. M. K., Halliwill, K. D., To, M. D., Rashid, M., Rust, A. G., Keane, T., Delrosario, R., Jen, K., Gurley, K. E., Kemp, C. J., et al. (2014) · Nature · doi:10.1038/nature13898 · Cited by 333 · see citing works

Acquired BRAF inhibitor resistance: A multicenter meta-analysis of the spectrum and frequencies, clinical behaviour, and phenotypic associations of resistance mechanisms

Johnson, D. B., Menzies, A. M., Zimmer, L., Eroglu, Z., Ye, F., Zhao, S., Rizos, H., Sucker, A., Scolyer, R. A., Gutzmer, R., et al. (2015) · European Journal of Cancer · doi:10.1016/j.ejca.2015.08.022 · Cited by 324 · see citing works

The Generation and Application of Patient-Derived Xenograft Model for Cancer Research

Jung, J., Seol, H. S., & Chang, S. (2017) · Cancer Research and Treatment · doi:10.4143/crt.2017.307 · Cited by 313 · see citing works

Translational value of mouse models in oncology drug development

Gould, S. E., Junttila, M. R., & de Sauvage, F. J. (2015) · Nature Medicine · doi:10.1038/nm.3853 · Cited by 293 · see citing works

Organoid cultures from normal and cancer-prone human breast tissues preserve complex epithelial lineages

Rosenbluth, J. M., Schackmann, R. C. J., Gray, G. K., Selfors, L. M., Li, C. M.-C., Boedicker, M., Kuiken, H. J., Richardson, A. L., Brock, J. E., Garber, J. E., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-15548-7 · Cited by 277 · see citing works

Application of Highly Immunocompromised Mice for the Establishment of Patient-Derived Xenograft (PDX) Models

Okada, S., Vaeteewoottacharn, K., & Kariya, R. (2019) · Cells · doi:10.3390/cells8080889 · Cited by 264 · see citing works

The Hedgehog Signaling Pathway in Cancer

Evangelista, M., Tian, H., & de Sauvage, F. J. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1736 · Cited by 247 · see citing works

Mapping Optogenetically Driven Single-Vessel fMRI with Concurrent Neuronal Calcium Recordings in the Rat Hippocampus

Chen, X., Sobczak, F., Chen, Y., Jiang, Y., Qian, C., Lu, Z., Ayata, C., Logothetis, N. K., & Yu, X. (2019) · Nature Communications · doi:10.1038/s41467-019-12850-x · Cited by 241 · see citing works

Transplantation of engineered organoids enables rapid generation of metastatic mouse models of colorectal cancer

O’Rourke, K. P., Loizou, E., Livshits, G., Schatoff, E. M., Baslan, T., Manchado, E., Simon, J. M., Romesser, P. B., Leach, B. I., Han, T., et al. (2017) · Nature Biotechnology · doi:10.1038/nbt.3837 · Cited by 237 · see citing works

Tolerability of BRAF/MEK inhibitor combinations: adverse event evaluation and management

Heinzerling, L., Eigentler, T., Fluck, M., Hassel, J. C., Heller-Schenck, D., Leipe, J., Pauschinger, M., Vogel, A., Zimmer, L., & Gutzmer, R. (2019) · ESMO Open · doi:10.1136/esmoopen-2019-000491 · Cited by 236 · see citing works

Oncogenic BRAF Is Required for Tumor Growth and Maintenance in Melanoma Models

Hoeflich, K. P., Gray, D. C., Eby, M. T., Tien, J., Wong, L. L.-Y., Bower, J., Gogineni, A., Zha, J., Cole, M. J., Stern, H. M., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-2720 · Cited by 233 · see citing works

Patient-derived explants (PDEs) as a powerful preclinical platform for anti-cancer drug and biomarker discovery

Powley, I. R., Patel, M., Miles, G. J., Pringle, H., Howells, L. M., Thomas, A., Kettleborough, C. A., Bryans, J. S., Hammonds, T. R., MacFarlane, M., et al. (2020) · British Journal of Cancer · doi:10.1038/s41416-019-0672-6 · Cited by 221 · see citing works

Genomic evolution of cancer models: perils and opportunities

Ben‐David, U., Beroukhim, R., & Golub, T. R. (2018) · Nature reviews. Cancer · doi:10.1038/s41568-018-0095-3 · Cited by 220 · see citing works

Emerging organoid models: leaping forward in cancer research

Fan, H., Demirci, U., & Chen, P. (2019) · Journal of Hematology &amp; Oncology · doi:10.1186/s13045-019-0832-4 · Cited by 199 · see citing works

Syngeneic mouse mammary carcinoma cell lines: Two closely related cell lines with divergent metastatic behavior

Borowsky, A. D., Namba, R., Young, L. J. T., Hunter, K. W., Hodgson, J., Tepper, C. G., McGoldrick, E. T., Muller, W. J., Cardiff, R. D., & Gregg, J. P. (2005) · Clinical & Experimental Metastasis · doi:10.1007/s10585-005-2908-5 · Cited by 195 · see citing works

Mutational landscape of <i>EGFR-</i> , <i>MYC-</i> , and <i>Kras-</i> driven genetically engineered mouse models of lung adenocarcinoma

McFadden, D. G., Politi, K., Bhutkar, A., Chen, F. K., Song, X., Pirun, M., Santiago, P. M., Kim-Kiselak, C., Platt, J. T., Lee, E., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1613601113 · Cited by 194 · see citing works

Emergence of Epidermal Growth Factor Receptor T790M Mutation during Chronic Exposure to Gefitinib in a Non–Small Cell Lung Cancer Cell Line

Ogino, A., Kitao, H., Hirano, S., Uchida, A., Ishiai, M., Kozuki, T., Takigawa, N., Takata, M., Kiura, K., & Tanimoto, M. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-0681 · Cited by 193 · see citing works

CRISPR/Cas9 somatic multiplex-mutagenesis for high-throughput functional cancer genomics in mice

Weber, J., Öllinger, R., Friedrich, M., Ehmer, U., Barenboim, M., Steiger, K., Heid, I., Mueller, S., Maresch, R., Engleitner, T., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1512392112 · Cited by 191 · see citing works

Comparison of the molecular and cellular phenotypes of common mouse syngeneic models with human tumors

Zhong, W., Myers, J. S., Wang, F., Wang, K., Lucas, J., Rosfjord, E. C., Lucas, J., Hooper, A. T., Yang, S., Lemon, L., et al. (2020) · BMC Genomics · doi:10.1186/s12864-019-6344-3 · Cited by 186 · see citing works

Resistance to Selective BRAF Inhibition Can Be Mediated by Modest Upstream Pathway Activation

Su, F., Bradley, W. D., Wang, Q., Yang, H. Y., Xu, L., Higgins, B., Kolinsky, K. D., Packman, K. E., Kim, M. J., Trunzer, K., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-1875 · Cited by 179 · see citing works

Phase 2 study of vismodegib, a hedgehog inhibitor, combined with gemcitabine and nab-paclitaxel in patients with untreated metastatic pancreatic adenocarcinoma

Jesus‐Acosta, A. D., Sugar, E. A., O'Dwyer, P. J., Ramanathan, R. K., Hoff, D. D. V., Rasheed, Z. A., Zheng, L., Begum, A., Anders, R. A., Maitra, A., et al. (2019) · British Journal of Cancer · doi:10.1038/s41416-019-0683-3 · Cited by 176 · see citing works

Mutations in BRAF and KRAS Converge on Activation of the Mitogen-Activated Protein Kinase Pathway in Lung Cancer Mouse Models

Ji, H., Wang, Z., Perera, S. A., Li, D., Liang, M., Zaghlul, S., McNamara, K. L., Chen, L., Albert, M., Sun, Y., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-4592 · Cited by 174 · see citing works

CRISPR-Cas9–mediated gene knockout in intestinal tumor organoids provides functional validation for colorectal cancer driver genes

Takeda, H., Kataoka, S., Nakayama, M., Ali, M. A. E., Oshima, H., Yamamoto, D., Park, J.-W., Takegami, Y., An, T., Jenkins, N. A., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1904714116 · Cited by 172 · see citing works

The organoid cell atlas

the Human Cell Atlas ‘Biological Network’ Organoids, Bock, C., Boutros, M., Camp, J. G., Clarke, L., Clevers, H., Knoblich, J. A., Liberali, P., Regev, A., Rios, A. C., et al. (2021) · Nature Biotechnology · doi:10.1038/s41587-020-00762-x · Cited by 171 · see citing works

Efficient Use of Patient-Derived Organoids as a Preclinical Model for Gynecologic Tumors

Maru, Y., Tanaka, N., Itami, M., & Hippo, Y. (2019) · Gynecologic Oncology · doi:10.1016/j.ygyno.2019.05.005 · Cited by 162 · see citing works

Comprehensive transcriptomic analysis of cell lines as models of primary tumors across 22 tumor types

Yu, K., Chen, B., Aran, D., Charalel, J. K., Yau, C. S. F., Wolf, D. M., Veer, L. V. ‘., Butte, A. J., Goldstein, T. C., & Sirota, M. (2019) · Nature Communications · doi:10.1038/s41467-019-11415-2 · Cited by 158 · see citing works

Patient‐derived xenografts for individualized care in advanced sarcoma

Stebbing, J., Paz, K., Schwartz, G. K., Wexler, L. H., Maki, R. G., Pollock, R. E., Morris, R., Cohen, R., Shankar, A., Blackman, G., et al. (2014) · Cancer · doi:10.1002/cncr.28696 · Cited by 156 · see citing works

A Comprehensive Patient-Derived Xenograft Collection Representing the Heterogeneity of Melanoma

Krepler, C., Sproesser, K., Brafford, P. A., Beqiri, M., Garman, B., Xiao, M., Shannan, B., Watters, A. K., Perego, M., Zhang, G., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.10.021 · Cited by 151 · see citing works

The new-generation selective ROS1/NTRK inhibitor DS-6051b overcomes crizotinib resistant ROS1-G2032R mutation in preclinical models

Katayama, R., Gong, B., Togashi, N., Miyamoto, M., Kiga, M., Iwasaki, S., Kamai, Y., Tominaga, Y., Takeda, Y., Kagoshima, Y., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-11496-z · Cited by 147 · see citing works

CRISPR/Cas9 mutagenesis invalidates a putative cancer dependency targeted in on-going clinical trials

Lin, A., Giuliano, C. J., Sayles, N. M., & Sheltzer, J. M. (2017) · eLife · doi:10.7554/elife.24179 · Cited by 145 · see citing works

Physiologically Based Pharmacokinetic Modelling for First-In-Human Predictions: An Updated Model Building Strategy Illustrated with Challenging Industry Case Studies

Miller, N. A., Reddy, M. B., Heikkinen, A. T., Lukacova, V., & Parrott, N. (2019) · Clinical Pharmacokinetics · doi:10.1007/s40262-019-00741-9 · Cited by 142 · see citing works

Antitumor activity of targeted and cytotoxic agents in murine subcutaneous tumor models correlates with clinical response

Wong, H., Choo, E. F., Alicke, B., Ding, X., La, H., McNamara, E., Theil, F.-P., Tibbitts, J., Friedman, L. S., Hop, C. E. C. A., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-0738 · Cited by 133 · see citing works

Exploiting evolutionary steering to induce collateral drug sensitivity in cancer

Acar, A., Nichol, D., Fernández-Mateos, J., Cresswell, G. D., Barozzi, I., Hong, S. P., Trahearn, N., Spiteri, I., Stubbs, M., Burke, R., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-15596-z · Cited by 131 · see citing works

Mouse Cutaneous Melanoma Induced by Mutant BRaf Arises from Expansion and Dedifferentiation of Mature Pigmented Melanocytes

Köhler, C., Nittner, D., Rambow, F., Radaelli, E., Stanchi, F., Vandamme, N., Baggiolini, A., Sommer, L., Berx, G., van den Oord, J. J., et al. (2017) · Cell Stem Cell · doi:10.1016/j.stem.2017.08.003 · Cited by 126 · see citing works

Mapping the in vivo fitness landscape of lung adenocarcinoma tumor suppression in mice

Rogers, Z. N., McFarland, C. D., Winters, I. P., Seoane, J. A., Brady Jennifer, J., Yoon, S. M., Curtis, C. N., Petrov, D. A., & Winslow, M. M. (2018) · Nature Genetics · doi:10.1038/s41588-018-0083-2 · Cited by 125 · see citing works

Development of New Mouse Lung Tumor Models Expressing EGFR T790M Mutants Associated with Clinical Resistance to Kinase Inhibitors

Regales, L., Balak, M. N., Gong, Y., Politi, K. A., Sawai, A., Le, C. H., Koutcher, J. A., Solit, D. B., Rosen, N. X., Zakowski, M. F., et al. (2007) · PLoS ONE · doi:10.1371/journal.pone.0000810 · Cited by 124 · see citing works

The fidelity of cancer cells in PDX models: Characteristics, mechanism and clinical significance

Shi, J., Li, Y., Jia, R., & Fan, X. (2019) · International Journal of Cancer · doi:10.1002/ijc.32662 · Cited by 118 · see citing works

Cancer drug development: The missing links

Kunnumakkara, A. B., Bordoloi, D., Sailo, B. L., Roy, N. K., Thakur, K. K., Banik, K., Shakibaei, M., Gupta, S. C., & Aggarwal, B. B. (2019) · Experimental Biology and Medicine · doi:10.1177/1535370219839163 · Cited by 114 · see citing works

Activating BRAF and PIK3CA Mutations Cooperate to Promote Anaplastic Thyroid Carcinogenesis

Charles, R., Silva, J. M., Iezza, G., Phillips, W. A., & McMahon, M. (2014) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-14-0158-t · Cited by 104 · see citing works

Factors associated with failure of oncology drugs in late-stage clinical development: A systematic review

Jardim, D. L. F., Groves, E. S., Breitfeld, P. P., & Kurzrock, R. (2016) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2016.10.009 · Cited by 101 · see citing works

TRK Inhibition: A New Tumor-Agnostic Treatment Strategy

Kummar, S., & Lassen, U. (2018) · Targeted Oncology · doi:10.1007/s11523-018-0590-1 · Cited by 98 · see citing works

MAPK pathway in melanoma part II—secondary and adaptive resistance mechanisms to BRAF inhibition

Amaral, T. M. S., Sinnberg, T. W., Meier, F. E., Krepler, C., Levesque, M. P., Niessner, H., & Garbe, C. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2016.12.012 · Cited by 93 · see citing works

Genetically engineered mouse models of cancer reveal new insights about the antitumor immune response

DuPage, M. J. P., & Jacks, T. (2013) · Current Opinion in Immunology · doi:10.1016/j.coi.2013.02.005 · Cited by 91 · see citing works

Modeling Tumor Immunology and Immunotherapy in Mice

Buqué, A., & Galluzzi, L. (2018) · Trends in cancer · doi:10.1016/j.trecan.2018.07.003 · Cited by 88 · see citing works

Erlotinib resistance in mouse models of epidermal growth factor receptor-induced lung adenocarcinoma

Politi, K. A., Fan, P., Shen, R., Zakowski, M. F., & VARMUS, H. E. (2009) · Disease Models & Mechanisms · doi:10.1242/dmm.003681 · Cited by 86 · see citing works

RAS Mutations in Cutaneous Squamous-Cell Carcinomas in Patients Treated with BRAF Inhibitors

McCullough, A. J. (2013) · Yearbook of Pathology and Laboratory Medicine · doi:10.1016/j.ypat.2012.10.041 · Cited by 84 · see citing works

Risk factors associated with having a pressure ulcer: a secondary data analysis.

Maklebust, J., & Magnan, M. A. (1994) · PubMed · Cited by 79 · see citing works

Relating hepatocellular carcinoma tumor samples and cell lines using gene expression data in translational research

Chen, B., Sirota, M., Fan-Minogue, H., Hadley, D., & Butte, A. J. (2015) · BMC Medical Genomics · doi:10.1186/1755-8794-8-s2-s5 · Cited by 77 · see citing works

Roles of tumor heterogeneity in the development of drug resistance: A call for precision therapy

Wu, D., Wang, D. C., Cheng, Y., Qian, M., Zhang, M., Shen, Q., & Wang, X. (2016) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2016.11.006 · Cited by 76 · see citing works

Multiregion gene expression profiling reveals heterogeneity in molecular subtypes and immunotherapy response signatures in lung cancer

Lee, W.-C., Diao, L., Wang, J., Zhang, J., Roarty, E. B., Varghese, S., Chow, C.-W. B., Fujimoto, J., Behrens, C., Cascone, T., et al. (2018) · Modern Pathology · doi:10.1038/s41379-018-0029-3 · Cited by 73 · see citing works

The Evolutionary Landscape of Treatment for BRAFV600E Mutant Metastatic Colorectal Cancer

Mauri, G., Bonazzina, E., Amatu, A., Tosi, F., Bencardino, K., Gori, V., Massihnia, D., Cipani, T., Spina, F., Ghezzi, S., et al. (2021) · Cancers · doi:10.3390/cancers13010137 · Cited by 73 · see citing works

Understanding the molecular mechanisms driving metastasis

Massagué, J., Batlle, E., & Gomis, R. R. (2017) · Molecular Oncology · doi:10.1002/1878-0261.12024 · Cited by 71 · see citing works

Drug Sensitivity and Allele Specificity of First-Line Osimertinib Resistance EGFR Mutations

Starrett, J. H., Guernet, A. A., Cuomo, M. E., Poels, K. E., van Rosenburgh, I. K. V. A., Nagelberg, A. L., Farnsworth, D., Price, K. S., Khan, H., Ashtekar, K. D., et al. (2020) · Cancer Research · doi:10.1158/0008-5472.can-19-3819 · Cited by 62 · see citing works

Kras mutant genetically engineered mouse models of human cancers are genomically heterogeneous

Chung, W., Daemen, A., Cheng, J. H., Long, J. E., Cooper, J. E., Wang, B.-E., Tran, C., Singh, M., Gnad, F., Modrusan, Z. D., et al. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1708391114 · Cited by 61 · see citing works

Discovering and validating cancer genetic dependencies: approaches and pitfalls

Lin, A., & Sheltzer, J. M. (2020) · Nature Reviews Genetics · doi:10.1038/s41576-020-0247-7 · Cited by 59 · see citing works

Analysis of erythrocyte signalling pathways during Plasmodium falciparum infection identifies targets for host-directed antimalarial intervention

Adderley, J., von Freyend, S. J., Jackson, S. A., Bird, M. J., Burns, A. L., Anar, B., Metcalf, T., Semblat, J., Billker, O., Wilson, D. W., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-17829-7 · Cited by 57 · see citing works

Towards quantitative and multiplexed in vivo functional cancer genomics

Winters, I. P., Murray, C. W., & Winslow, M. M. (2018) · Nature Reviews Genetics · doi:10.1038/s41576-018-0053-7 · Cited by 53 · see citing works

Genetically Engineered Mouse Models of Prostate Cancer in the Postgenomic EraPreprint

Arriaga, J. M., & Abate-Shen, C. T. (2018) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a030528 · Cited by 51 · see citing works

New drug approvals in oncology

Kurzrock, R., Kantarjian, H. M., Kesselheim, A. S., & Sigal, E. V. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0313-2 · Cited by 50 · see citing works

The landscape of BRAF transcript and protein variants in human cancer

Marranci, A., Jiang, Z., Vitiello, M., Guzzolino, E., Comelli, L., Sarti, S., Lubrano, S., Franchin, C., Echevarría-Vargas, I. M., Tuccoli, A., et al. (2017) · Molecular Cancer · doi:10.1186/s12943-017-0645-4 · Cited by 48 · see citing works

Organoid modeling for cancer precision medicine

Cantrell, M. A., & Kuo, C. J. (2015) · Genome Medicine · doi:10.1186/s13073-015-0158-y · Cited by 41 · see citing works

Genetically Engineered Cancer Models, But Not Xenografts, Faithfully Predict Anticancer Drug Exposure in Melanoma Tumors

Combest, A. J., Roberts, P. J., Dillon, P. M., Sandison, K., Hanna, S. K., Ross, C., Habibi, S., Zamboni, B. A., Müller, M., Brunner, M., et al. (2012) · The Oncologist · doi:10.1634/theoncologist.2012-0274 · Cited by 41 · see citing works

The Raf Inhibitor Paradox: Unexpected Consequences of Targeted Drugs

Cox, A. D., & Der, C. J. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.02.029 · Cited by 40 · see citing works

Therapeutic resistance and susceptibility is shaped by cooperative multi-compartment tumor adaptation

Long, J. E., Wongchenko, M. J., Nickles, D., Chung, W., Wang, B.-E., Riegler, J., Li, J., Li, Q., Sandoval, W. N., Eastham-Anderson, J., et al. (2019) · Cell Death and Differentiation · doi:10.1038/s41418-019-0310-0 · Cited by 37 · see citing works

More than fishing for a cure: The promises and pitfalls of high throughput cancer cell line screens

Ling, A. L., Gruener, R. F., Fessler, J. L., & Huang, R. S. (2018) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.06.014 · Cited by 35 · see citing works

Engineering CRISPR mouse models of cancer

Weber, J., & Rad, R. (2019) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2019.04.001 · Cited by 33 · see citing works

Precious GEMMs: emergence of faithful models for ovarian cancer research

Stückelberger, S., & Drapkin, R. (2018) · The Journal of Pathology · doi:10.1002/path.5065 · Cited by 28 · see citing works

Prediction of active human dose: learnings from 20 years of Merck KGaA experience, illustrated by case studies

Peters, S. A., Petersson, C., Blaukat, A., Halle, J.-P., & Dolgos, H. (2020) · Drug Discovery Today · doi:10.1016/j.drudis.2020.01.002 · Cited by 28 · see citing works

Prolonged Response to HER2-Directed Therapy in a Patient With HER2-Amplified, Rapidly Progressive Metastatic Colorectal Cancer

Parikh, A. R., Atreya, C. E., Korn, W. M., & Venook, A. P. (2016) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2017.0002 · Cited by 27 · see citing works

Stem Cells and Organoid Technology in Precision Medicine in Inflammation: Are We There Yet?

Tran, F., Klein, C., Arlt, A., Imm, S., Knappe, E., Simmons, A., Rosenstiel, P. C., & Seibler, P. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.573562 · Cited by 25 · see citing works

Increasing aggressiveness of patient-derived xenograft models of cervix carcinoma during serial transplantation

Wegner, C. S., Hauge, A., Andersen, L. M. K., Huang, R., Simonsen, T. G., Gaustad, J., & Rofstad, E. K. (2018) · Oncotarget · doi:10.18632/oncotarget.24783 · Cited by 20 · see citing works

Transcriptional Subtypes Resolve Tumor Heterogeneity and Identify Vulnerabilities to MEK Inhibition in Lung Adenocarcinoma

Daemen, A., Cooper, J. E., Myrta, S., Wongchenko, M. J., Lin, E., Long, J. E., Foreman, O., Modrusan, Z. D., Tremayne, J. R., de la Cruz, C. C., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-1835 · Cited by 20 · see citing works

Development of Personalized Therapeutic Strategies by Targeting Actionable Vulnerabilities in Metastatic and Chemotherapy-Resistant Breast Cancer PDXs

Punzi, S., Melixetian, M. B., Riva, L., Marocchi, F., Pruneri, G., Criscitiello, C., Orsi, F., Spaggiari, L., Casiraghi, M., Vigna, P. D., et al. (2019) · Cells · doi:10.3390/cells8060605 · Cited by 19 · see citing works

Cell line-based xenograft mouse model of paediatric glioma stem cells mirrors the clinical course of the patient

Larsson, S. C., Wenger, A., Dósa, S., Sabel, M., Kling, T., & Carén, H. (2018) · Carcinogenesis · doi:10.1093/carcin/bgy091 · Cited by 18 · see citing works

Multiregion Genomic Analysis of Serially Transplanted Patient-derived Xenograft Tumors

Sato, K., Niida, A., Masuda, T., Shimizu, D., Tobo, T., Kuroda, Y., Eguchi, H., Nakagawa, T., Suzuki, Y., & Mimori, K. (2018) · Cancer Genomics & Proteomics · doi:10.21873/cgp.20109 · Cited by 16 · see citing works

Organoids as Oracles for Precision Medicine in Rectal Cancer

Kolahi, K. S., Nakano, M., & Kuo, C. J. (2020) · Cell stem cell · doi:10.1016/j.stem.2019.12.003 · Cited by 13 · see citing works

A Syngeneic ErbB2 Mammary Cancer Model for Preclinical Immunotherapy Trials

Pénzváltó, Z., Chen, J. Q., Tepper, C. G., Davis, R. R., Silvestrini, M. T., Umeh-Garcia, M. C., Sweeney, C. A., & Borowsky, A. D. (2019) · Journal of Mammary Gland Biology and Neoplasia · doi:10.1007/s10911-019-09425-3 · Cited by 9 · see citing works

Insights into the FDA 2018 New Drug Approvals

Bedair, A., & Mansour, F. R. (2019) · Current Drug Discovery Technologies · doi:10.2174/1570163816666191202104315 · Cited by 9 · see citing works

Calcium transport by a β-diketone in model membranes

Deleers, M., Brasseur, R., & Malaisse, W. J. (1983) · Chemistry and Physics of Lipids · doi:10.1016/0009-3084(83)90003-8 · Cited by 8 · see citing works

Drug Sensitivity and Allele‐specificity of First‐line Osimertinib Resistance EGFR Mutations

Starrett, J. H., Guernet, A. A., Cuomo, M. E., Poels, K. E., van Rosenburgh, I. K. V. A., Nagelberg, A. L., Farnsworth, D., Price, K. S., Khan, H., Ashtekar, K. D., et al. (2020) · The FASEB Journal · doi:10.1096/fasebj.2020.34.s1.00612 · Cited by 7 · see citing works

EGFR-Mediated Re-Activation of MAPK Signaling Contributes to Insensitivity of BRAF Mutant Colorectal Cancers to RAF Inhibition

Ebi, H. (2012) · Annals of Oncology · doi:10.1016/s0923-7534(20)32033-0 · Cited by 6 · see citing works

[The effects of extracts of malignant neoplasms on immunologic reactions].

Na, S., SAVCHUK, O. E., & Tf, K. (1968) · PubMed · Cited by 5 · see citing works

Abstract 1697: Humanized immune-oncology mouse models

Stecklum, M., Wulf-Goldenberg, A., Brzezicha, B., Fichtner, I., & Hoffmann, J. (2017) · Cancer Research · doi:10.1158/1538-7445.am2017-1697 · Cited by 3 · see citing works

Patient-Derived Xenograft (PDX) Models: An Emerging Platform for Cancer Drug Development and Translational Research

Murphy, J. F. (2016) · MOJ Immunology · doi:10.15406/moji.2016.03.00094 · Cited by 2 · see citing works

Predicting tumor-immune response to checkpoint inhibitors using a novel patient-derived live tumor explant model.

Radhakrishnan, P., Goldman, A. J., Ulaganathan, B., Kumar, A. T., Maciejko, L., Gertje, H. P., Shanthappa, B., Mehrotra, D. G., Biswas, M., Thiyagarajan, S., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.35.15_suppl.e20035 · Cited by 2 · see citing works

[Differentiation of Bordetella bronchiseptica strains. 3. Brief study of different reaction of various mouse lines to Bordetella bronchiseptica strains].

Hoffmann, A., Krüger, M., & Horsch, F. (1984) · PubMed · Cited by 1 · see citing works

[Health policy--dangerous to be alive].

Fasting, U. (1994) · PubMed · Cited by 1 · see citing works

Melanoma Model Systems

Schittek, B., de Jel, M. M., & Tüting, T. (2017) · Springer eBooks · doi:10.1007/978-3-319-41319-8_15 · Cited by 1 · see citing works

Organoids

Zhao, Z., Chen, X., Dowbaj, A. M., Sljukic, A., Bratlie, K., Lin, L., Fong, E. L. S., Balachander, G. M., Chen, Z., Soragni, A., et al. (2022) · Nature Reviews Methods Primers · doi:10.1038/s43586-022-00174-y · Cited by 1,001 · see citing works

Patient-derived xenograft models in cancer therapy: technologies and applications

Liu, Y., Wu, W., Cai, C., Zhang, H., Shen, H., & Han, Y. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01419-2 · Cited by 524 · see citing works

Drug resistance in cancer: molecular mechanisms and emerging treatment strategies

Li, J., Hu, J., Yang, Y., Zhang, H., Liu, Y., Fang, Y., Qu, L., Lin, A., Luo, P., Jiang, A., et al. (2025) · Molecular Biomedicine · doi:10.1186/s43556-025-00352-w · Cited by 101 · see citing works

Coding, or non-coding, that is the question

Poliseno, L., Lanza, M., & Pandolfi, P. P. (2024) · Cell Research · doi:10.1038/s41422-024-00975-8 · Cited by 96 · see citing works

Personalized chordoma organoids for drug discovery studies

Al Shihabi, A., Davarifar, A., Nguyen, H. T. L., Tavanaie, N., Nelson, S. D., Yanagawa, J., Federman, N., Bernthal, N., Hornicek, F., & Soragni, A. (2022) · Science Advances · doi:10.1126/sciadv.abl3674 · Cited by 75 · see citing works

A multi-organ-on-chip to recapitulate the infiltration and the cytotoxic activity of circulating NK cells in 3D matrix-based tumor model

Marzagalli, M., Pelizzoni, G., Fedi, A., Vitale, C., Fontana, F., Bruno, S., Poggi, A. D., Dondero, A., Aiello, M., Castriconi, R., et al. (2022) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2022.945149 · Cited by 63 · see citing works

Recommendations for robust and reproducible preclinical research in personalised medicine

Fosse, V., Oldoni, E., Biétrix, F., Budillon, A., Daskalopoulos, E. P., Fratelli, M., Gerlach, B., Groenen, P. M. A., Hölter, S. M., Menon, J. M. L., et al. (2023) · BMC Medicine · doi:10.1186/s12916-022-02719-0 · Cited by 55 · see citing works

PharmaFormer predicts clinical drug responses through transfer learning guided by patient derived organoid

Zhou, Y., Dai, Q., Xu, Y., Wu, S., Cheng, M., & Zhao, B. T. (2025) · npj Precision Oncology · doi:10.1038/s41698-025-01082-6 · Cited by 48 · see citing works

Deep transfer learning for clinical decision-making based on high-throughput data: comprehensive survey with benchmark results

Toseef, M., Petinrin, O. O., Wang, F., Rahaman, S., Liu, Z., Li, X., & Wong, K. (2023) · Briefings in Bioinformatics · doi:10.1093/bib/bbad254 · Cited by 41 · see citing works

Serrated colorectal cancer: preclinical models and molecular pathways

Aiderus, A., Barker, N., & Tergaonkar, V. (2023) · Trends in cancer · doi:10.1016/j.trecan.2023.09.011 · Cited by 42 · see citing works

Resurgence of syphilis: focusing on emerging clinical strategies and preclinical models

Xiong, S., Liu, Z., Zhang, X., Huang, S., Ding, X., Zhou, J., Yao, J., Li, W., Liu, S., & Zhao, F. (2023) · Journal of Translational Medicine · doi:10.1186/s12967-023-04685-4 · Cited by 40 · see citing works

Predicting drug–target binding affinity with cross-scale graph contrastive learning

Wang, J., Xiao, Y., Shang, X., & Peng, J. (2023) · Briefings in Bioinformatics · doi:10.1093/bib/bbad516 · Cited by 38 · see citing works

OBSERVE: guidelines for the refinement of rodent cancer models

Vleeschauwer, S. I. D., van de Ven, M., Oudin, A., Debusschere, K., Connor, K., Byrne, A. T., Ram, D., Rhebergen, A. M., Raeves, Y. D., Dahlhoff, M., et al. (2024) · Nature Protocols · doi:10.1038/s41596-024-00998-w · Cited by 40 · see citing works

Computational estimation of quality and clinical relevance of cancer cell lines

Trastulla, L., Noorbakhsh, J., Vazquez, F., McFarland, J., & Iorio, F. (2022) · Molecular Systems Biology · doi:10.15252/msb.202211017 · Cited by 31 · see citing works

In vitro construction of lung cancer organoids by 3D bioprinting for drug evaluation

Dong, Q., Su, X., Li, X., Zhou, H., Jian, H., Bai, S., Yin, J., & You, Q. (2023) · Colloids and Surfaces A Physicochemical and Engineering Aspects · doi:10.1016/j.colsurfa.2023.131288 · Cited by 29 · see citing works

Next‐Generation Preclinical Functional Testing Models in Cancer Precision Medicine: CTC‐Derived Organoids

Huang, L., Xu, Y., Wang, N., Yi, K., Xi, X., Si, H., Zhang, Q., Xiang, M., Rong, Y., Yuan, Y., et al. (2023) · Small Methods · doi:10.1002/smtd.202301009 · Cited by 27 · see citing works

Early phase clinical trials in oncology: Realising the potential of seamless designs

Jaki, T., Burdon, A., Chen, X., Mozgunov, P., Zheng, H., & Baird, R. D. (2023) · European Journal of Cancer · doi:10.1016/j.ejca.2023.05.005 · Cited by 23 · see citing works

Exploring New Dimensions of Tumor Heterogeneity: The Application of Single Cell Analysis to Organoid‐Based 3D In Vitro Models

Landon‐Brace, N., Li, N. T., & McGuigan, A. P. (2023) · Advanced Healthcare Materials · doi:10.1002/adhm.202300903 · Cited by 24 · see citing works

Combination drug screen targeting glioblastoma core vulnerabilities reveals pharmacological synergisms

Ariey-Bonnet, J., Bergès, R., Montero, M.-P., Mouysset, B., Piris, P., Müller, K., Pinna, G., Failes, T. W., Arndt, G. M., Morando, P., et al. (2023) · EBioMedicine · doi:10.1016/j.ebiom.2023.104752 · Cited by 22 · see citing works

Salicylanilides and Their Anticancer Properties

Kauerová, T., Pérez‐Pérez, M., & Kollár, P. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24021728 · Cited by 21 · see citing works

Experimental evidence of quint points and non-quantum chirality in a minimalist autonomous electronic oscillator

VOLOS, C. K., & Gallas, J. A. C. (2022) · The European Physical Journal Plus · doi:10.1140/epjp/s13360-021-02318-7 · Cited by 20 · see citing works

Large inherent variability in data derived from highly standardised cell culture experiments

Reddin, I. G., Fenton, T. R., Wass, M. N., & Michaelis, M. (2023) · Pharmacological Research · doi:10.1016/j.phrs.2023.106671 · Cited by 20 · see citing works

Investigating the potential of oncolytic viruses for cancer treatment via MSC delivery

Ghaleh, H. E. G., Vakilzadeh, G., Zahiri, A., & Farzanehpour, M. (2023) · Cell Communication and Signaling · doi:10.1186/s12964-023-01232-y · Cited by 19 · see citing works

Transfer learning of clinical outcomes from preclinical molecular data, principles and perspectives

Kowald, A., Barrantes, I., Möller, S., Palmer, D. H., Escobar, H. M., Schwerk, A. M. K., & Fuellen, G. (2022) · Briefings in Bioinformatics · doi:10.1093/bib/bbac133 · Cited by 17 · see citing works

A Genetically Encoded Magnetic Resonance Imaging Reporter Enables Sensitive Detection and Tracking of Spontaneous Metastases in Deep Tissues

Nyström, N. N., McRae, S. W., Martínez, F. M., Kelly, J. J., Scholl, T. J., & Ronald, J. A. (2022) · Cancer Research · doi:10.1158/0008-5472.can-22-2770 · Cited by 16 · see citing works

The endocannabinoid system in cancer biology: a mini-review of mechanisms and therapeutic potential

Salum, K. C. R., Miranda, G. B. A., Dias, A. L., Carneiro, J. R. I., Bozza, P. T., da Fonseca, A. C. P., & Silva, T. (2025) · Oncology Reviews · doi:10.3389/or.2025.1573797 · Cited by 15 · see citing works

Capturing the third dimension in drug discovery: Spatially-resolved tools for interrogation of complex 3D cell models

Simão, D. F., Gomes, C. M., Alves, P. M., & Brito, C. (2021) · Biotechnology Advances · doi:10.1016/j.biotechadv.2021.107883 · Cited by 14 · see citing works

Homologous Recombination Deficiency Unrelated to Platinum and PARP Inhibitor Response in Cell Line Libraries

Takamatsu, S., Murakami, K., & Matsumura, N. (2024) · Scientific Data · doi:10.1038/s41597-024-03018-4 · Cited by 15 · see citing works

Ovarian Cancer Patient-Derived Organoid Models for Pre-Clinical Drug Testing

Fashemi, B., van Biljon, L., Rodriguez, J., Graham, O., Mullen, M., & Khabele, D. (2023) · Journal of Visualized Experiments · doi:10.3791/65068 · Cited by 15 · see citing works

The role of optimizers in developing data-driven model for predicting lake water quality incorporating advanced water quality model

Uddin, M. G., Bamal, A., Diganta, M. T. M., Sajib, A. M., Rahman, A., Abioui, M., & Olbert, A. I. (2025) · Alexandria Engineering Journal · doi:10.1016/j.aej.2025.03.022 · Cited by 14 · see citing works

Melanoma growth in non-chemically modified translucid bacterial nanocellulose hollow and compartimentalized spheres

Fucina, G., Cesca, K., Berti, F. V., Biavatti, M. W., & Porto, L. M. (2022) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2022.130183 · Cited by 13 · see citing works

Development and Characterization of an In Vitro Round Window Membrane Model for Drug Permeability Evaluations

Singh, R., Birru, B., Veit, J. G. S., Arrigali, E. M., & Serban, M. A. (2022) · Pharmaceuticals · doi:10.3390/ph15091105 · Cited by 13 · see citing works

Establishment and large-scale validation of a three-dimensional tumor model on an array chip for anticancer drug evaluation

Xiao, R., Jin, L., Xie, N., Luo, P., Gao, W., Tu, P., & Ai, X. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.1032975 · Cited by 13 · see citing works

Molecular and functional landscape of malignant serous effusions for precision oncology

Wegmann, R., Bankel, L., Festl, Y., Lau, K., Lee, S., Arnold, F. M., Cappelletti, V., Fehr, A., Picotti, P., Dedes, K. J., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-52694-8 · Cited by 14 · see citing works

Tyrosine Kinase Inhibitor Lenvatinib Based Nano Formulations and Cutting-Edge Scale-Up Technologies in revolutionizing Cancer Therapy

Shaikh, S., Chary, P. S., & Mehra, N. K. (2025) · ACS Applied Bio Materials · doi:10.1021/acsabm.4c01527 · Cited by 13 · see citing works

Emerging applications of stimulated Raman scattering microscopy for medicinal chemistry and drug discovery

Braddick, H. J., Tipping, W. J., Grant, E. K., Tomkinson, N. C. O., Faulds, K., & Graham, D. (2025) · Chemical Society Reviews · doi:10.1039/d5cs00748h · Cited by 10 · see citing works

A chronicle review of new techniques that facilitate the understanding and development of optimal individualized therapeutic strategies for chordoma

Zhao, C., Tan, T., Zhang, E., Wang, T., Gong, H., Jia, Q., Liu, T., Yang, X., Zhao, J., Wu, Z., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.1029670 · Cited by 9 · see citing works

Neuroimaging findings in preclinical amyotrophic lateral sclerosis models—How well do they mimic the clinical phenotype? A systematic review

Cannon, A. E., Zürrer, W. E., Zejlon, C., Kulcsár, Z., Lewandowski, S. A., Piehl, F., Granberg, T., & Ineichen, B. V. (2023) · Frontiers in Veterinary Science · doi:10.3389/fvets.2023.1135282 · Cited by 9 · see citing works

Cancer models for reverse and forward translation

(2022) · Nature Cancer · doi:10.1038/s43018-022-00346-5 · Cited by 8 · see citing works

Patient-derived tumoroids and proteomic signatures: tools for early drug discovery

Lê, H., Deforges, J., Cutolo, P., Lamarque, A., Hua, G., Lindner, V., Jain, S., Balloul, J., Benkirane-Jessel, N., & Quéméneur, É. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1379613 · Cited by 8 · see citing works

Leveraging Multimodal Foundation Models in Biliary Tract Cancer Research

Singh, Y., Andersen, J. B., Hathaway, Q. A., Vera-Garcia, D. V., Keishing, V., Venkatesh, S. K., Salehi, S., Povero, D., Wallace, M. B., Gores, G. J., et al. (2025) · Tomography · doi:10.3390/tomography11090096 · Cited by 7 · see citing works

Patient-derived models: Promising tools for accelerating the clinical translation of breast cancer research findings

Cao, C., Lu, X., Guo, X., Zhao, H., & Gao, Y. (2023) · Experimental Cell Research · doi:10.1016/j.yexcr.2023.113538 · Cited by 7 · see citing works

3D bioprinting of alginate for cancer therapy: A review

Rastin, H., & Abousalman‐Rezvani, Z. (2025) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2025.145494 · Cited by 6 · see citing works

Nanoformulated Phytochemicals Against Pancreatic Cancer: Emerging Advances in Therapeutic Strategies

Bravo-Vázquez, L. A., García, A. R., Maciel-Alemán, K., Rodríguez-González, G. Y., Sahare, P., Luna‐Bárcenas, G., Duttaroy, A. K., & Paul, S. (2026) · International Journal of Nanomedicine · doi:10.2147/ijn.s571767 · Cited by 6 · see citing works

Organoids, organ-on-a-chip, and microtumors: Biomimetic 3D tumor models advancing drug development and precision medicine

Xia, M., Wu, G., Wu, D., Hu, W., Deng, H., & Wang, S. (2026) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2026.03.013 · Cited by 7 · see citing works

The preclinical gap in pancreatic cancer and radiotherapy

Tesson, M., & Morton, J. P. (2024) · Disease Models & Mechanisms · doi:10.1242/dmm.050703 · Cited by 6 · see citing works

Multiparametric Longitudinal Profiling of RCAS-tva-Induced PDGFB-Driven Experimental Glioma

Becker, H., Vega, S. C., Patzwaldt, K., Przystal, J. M., Walter, B., MICHELOTTI, F. C., Canjuga, D., Tatagiba, M. S., Pichler, B. J., Beck, S. C., et al. (2022) · Brain Sciences · doi:10.3390/brainsci12111426 · Cited by 7 · see citing works

Modeling Liver Development and Disease in a Dish

Iqbal, W., Wang, Y., Sun, P., & Zhou, X. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242115921 · Cited by 6 · see citing works

Improved analysis of in vivo drug combination experiments with a comprehensive statistical framework and web-tool

Romero-Becerra, R., Zhao, Z. Q., Nebdal, D. J. H., Müller, E., Bergholtz, H., Norum, J. H., & Aittokallio, T. A. (2025) · Nature Communications · doi:10.1038/s41467-025-65218-9 · Cited by 5 · see citing works

Neuronal Organoid Engineering and Disease-Focused High-Throughput Neuropharmacology: Advances, Limitations, and Translational Strategies

Far, B. F., Omidvar, K., Heidari, E., Ebrahimi, M., Mohammadi, Y., & Ertaş, Y. N. (2025) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.5c00407 · Cited by 5 · see citing works

Cardiac magnetic resonance imaging characterization of acute rejection in a porcine heterotopic heart transplantation model

Mendiola, M., Milano, C. A., Glass, C., Bowles, D. E., & Wendell, D. C. (2024) · PLoS ONE · doi:10.1371/journal.pone.0304588 · Cited by 5 · see citing works

Translational Relevance and Future Integration of the Oncopig Cancer Model in Preclinical Applications

Elkhadragy, L., Gaba, R. C., Niemeyer, M. M., Schook, L. B., & Schachtschneider, K. M. (2024) · Annual Review of Animal Biosciences · doi:10.1146/annurev-animal-111523-102125 · Cited by 5 · see citing works

Biologically relevant integration of transcriptomics profiles from cancer cell lines, patient-derived xenografts, and clinical tumors using deep learning

Dimitrieva, S., Janssens, R., Li, G., Szałata, A., Gopalakrishnan, R., Parmar, C., Kauffmann, A., & Durand, E. Y. (2025) · Science Advances · doi:10.1126/sciadv.adn5596 · Cited by 5 · see citing works

Using Patient-Derived Xenograft (PDX) Models as a ‘Black Box’ to Identify More Applicable Patients for ADP-Ribose Polymerase Inhibitor (PARPi) Treatment in Ovarian Cancer: Searching for Novel Molecular and Clinical Biomarkers and Performing a Prospective Preclinical Trial

Chen, J., Li, Y., Wang, H., Li, T., Gu, Y. L., Wang, W., Shan, Y., Yin, J., Wang, Y., Qin, M., et al. (2022) · Cancers · doi:10.3390/cancers14194649 · Cited by 5 · see citing works

Critical Comments by Food and Drug Administration Reviewers on Patient-Reported Outcomes in Food and Drug Administration Regulatory Submissions (2018-2021)

Slota, C., Norcross, L., Comerford, E., Sasané, M., Zheng, Y., & Gnanasakthy, A. (2024) · Value in Health · doi:10.1016/j.jval.2024.02.011 · Cited by 4 · see citing works

Comparative Proteomic Characterization of Serum-Free Cultivated HepG2 Cells Reveals Upregulated Drug Metabolism and Increased Oxidative Stress Protection

Pfeifer, L.-M., Singh, J., Zimmer, A., Krenkel, M., Fischer, F., Sensbach, J., Pipp, F. C., Werkmann, D., & Hewitt, P. G. (2025) · Journal of Proteome Research · doi:10.1021/acs.jproteome.5c00100 · Cited by 4 · see citing works

A porcine model of acute rejection for cardiac transplantation

Mendiola, M., Chiang, Y. P., Glass, C., Wendell, D. C., Swain-Lenz, D., Ho, S., Fudim, M., Lee, F. H., Kang, L., Smith, M. F., et al. (2025) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2025.1549377 · Cited by 4 · see citing works

OrgXenomics: an integrated proteomic knowledge base for patient-derived organoid and xenograft

Zhang, Y., Lian, X., Xu, H., Zhu, S., Zhang, H., Ni, Z., Fu, T., Liu, S., Tao, L., Zhou, Y., et al. (2024) · Nucleic Acids Research · doi:10.1093/nar/gkae861 · Cited by 4 · see citing works

Bridging the Gap: How Organ‐on‐a‐Chip Technology Facilitates the Battle against Glioma

Liu, S., Gong, Z., Zhou, D., Ayala‐Nunez, V., Xu, T., & Wick, P. (2025) · Small Science · doi:10.1002/smsc.202500154 · Cited by 5 · see citing works

A high-throughput 3D culture microfluidic platform for multi-parameter phenotypic and omics profiling of patient-derived organoidsPreprint

Botrugno, O. A., Bianchi, E., Bruno, J. M., Gallo, G. F. M., Felici, C., Sommella, E., Stefano, P. D., Giansanti, V., Rossella, V., Merciai, F., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.12.28.630600 · Cited by 4 · see citing works

State of Research on Tissue Engineering with 3D Printing for Breast Reconstruction

Velasquez, G. D. D. S., Tanas, Y., Taraballi, F., Herzog, T., & Spiegel, A. J. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14196737 · Cited by 3 · see citing works

Murine models of lung adenocarcinoma: Valuable tools for preclinical investigation

Shang, W., Lai, C., Luo, S., & Chen, L. (2025) · Gene · doi:10.1016/j.gene.2025.149802 · Cited by 3 · see citing works

Harnessing PDX and PDX 2.0: the next-generation paradigm for precision oncology and translational breakthroughs

Jian, C., Fu, H., Wu, W., Zhang, N., Liu, Z., Xia, Z., Luo, P., Zhang, H., & Cheng, Q. (2026) · Molecular Cancer · doi:10.1186/s12943-026-02594-w · Cited by 4 · see citing works

Unveiling immune cell response disparities in human primary cancer-associated fibroblasts between two- and three-dimensional cultures

Yang, J.-P., Kulkarni, N. N., Yamaji, M., Shiraishi, T., Pham, T. Q., Do, H., Aiello, N. M., Shaw, M. H., Nakamura, T., Abiru, A., et al. (2024) · PLoS ONE · doi:10.1371/journal.pone.0314227 · Cited by 3 · see citing works

Synergistic Effect of Lenvatinib and Chemotherapy in Hepatocellular Carcinoma Using Preclinical Models

Wang, M., Yao, X., Bo, Z., Zheng, J., Yu, H., Xie, X., Lin, Z., Wang, Y., Chen, G., & Wu, L. (2023) · Journal of Hepatocellular Carcinoma · doi:10.2147/jhc.s395474 · Cited by 3 · see citing works

Completion Rate and Positive Results Reporting Among Immunotherapy Trials in Breast Cancer, 2004-2023

Mariani, M., Viale, G., Galbardi, B., Licata, L., Bosi, C., Dugo, M., Notini, G., Naldini, M. M., Callari, M., Criscitiello, C., et al. (2024) · JAMA Network Open · doi:10.1001/jamanetworkopen.2024.23390 · Cited by 3 · see citing works

Advancing Frontiers in Colorectal Cancer: Exploring Novel Insights and Emerging Trends in Research and Therapy

Ali, A. A. (2024) · Advancements in Life Sciences · doi:10.62940/als.v11i4.3335 · Cited by 3 · see citing works

Patient-Derived Xenografts of Breast Cancer

Marangoni, E. (2025) · Advances in experimental medicine and biology · doi:10.1007/978-3-031-70875-6_7 · Cited by 3 · see citing works

Sensitive Spatiotemporal Tracking of Spontaneous Metastasis in Deep Tissues via a Genetically-Encoded Magnetic Resonance Imaging ReporterPreprint

Nyström, N. N., McRae, S. W., Martinez, F. F. M., Kelly, J. J., Scholl, T. J., & Ronald, J. A. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.02.09.479610 · Cited by 3 · see citing works

Predicting PROTAC-targeted Degradation and Designing Androgen Receptor Degraders with AiPROTACPreprint

Zhang, L., Sun, R., Li, X., Ren, C., Long, Y., Tan, W., Wang, X., Zou, K., Yang, X., Wu, M., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.02.26.640266 · Cited by 3 · see citing works

Cathepsin C: a critical mediator between immune response and cardiovascular disease – therapeutic implications of enzyme inhibition

Aljabali, A. A. A., Obeid, M. A., Gammoh, O., Alshaer, W., Qnais, E. Y., Alqudah, A. M., Mishra, V. K., Mishra, Y., & El‐Tanani, M. (2025) · Drug Development and Industrial Pharmacy · doi:10.1080/03639045.2025.2571722 · Cited by 2 · see citing works

Advancing anticancer chelation therapy: Insights from enhancing cytotoxic potency, targeted cellular delivery, metal-based immunomodulation, and combinatorial strategies

Acosta, C., Claudio-Ares, O., Ullah, I., Cruz, L. C., Ducey, A. C., Vidal, A., Escalante-Castaneda, A., Maldonado-Santos, A. R., Liu, B., Villanueva, C. N., et al. (2025) · Inorganica Chimica Acta · doi:10.1016/j.ica.2025.123004 · Cited by 2 · see citing works

3D Tumor Models—Nanomedicine in the Third Dimension

Bravo, M. L., Zundert, I. V., Uji‐i, H., Fortuni, B., & Rocha, S. (2024) · Nanomedicine and nanotoxicology · doi:10.1007/978-981-97-5288-1_11 · Cited by 2 · see citing works

Experimental Modeling and Treatment Strategies for Peritoneal Carcinomatosis

Canda, A. E., & Sever, T. (2024) · Turkish Journal of Colorectal Disease · doi:10.4274/tjcd.galenos.2024.2024-10-5 · Cited by 2 · see citing works

BioXNet: a biologically inspired neural network for deciphering anti-cancer drug response in precision medicinePreprint

Yang, J., Wu, W. K. K., Hui, R. Y. M., Wong, I. C. K., & Zhang, Q. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.01.29.576766 · Cited by 2 · see citing works

Spatial artifact detection improves the reproducibility of drug screening experiments

Ianevski, A., Nader, K. M., Potdar, S., Gorbonos, A., Ianevski, F., Tanoli, Z., Saarela, J., & Aittokallio, T. A. (2025) · iScience · doi:10.1016/j.isci.2025.113470 · Cited by 1 · see citing works

Efficient drug–target affinity prediction via interaction features and parallel CNN–BiLSTM with attention

Cader, J. M. A., Newton, M. A. H., & Sattar, A. (2025) · Computational Biology and Chemistry · doi:10.1016/j.compbiolchem.2025.108862 · Cited by 2 · see citing works

Drug Repurposing In Modern Drug Discovery: Role of In Silico Study

Islam, K. M. T. (2025) · Pharmacon Jurnal Farmasi Indonesia · doi:10.23917/pharmacon.v22i2.13698 · Cited by 1 · see citing works

Computational Innovations in Cancer Research and How Computing is Transforming Drug Discovery and Development: A Review

Lytan, I., Singha, B., Boruah, N., Gogoi, P. P., Longkumer, P., Pucho, M., Dkhar, B., & Sinha, U. B. (2026) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/0113895575418750251204104229 · Cited by 1 · see citing works

Lycopene Nanoencapsulation and Cancer Treatment: A Systematic Review of Preclinical Evidence

Palomo, A. O., Ortíz, R., Prados, J. C., & Melguizo, C. (2026) · Applied Sciences · doi:10.3390/app16168159 · Cited by 1 · see citing works

Closing the recapitulation gap in obesity-conditioned TNBC drug development

Budhwani, K. I., Stringer-Reasor, E. M., Sorace, A. G., Buchsbaum, D. J., & Crawford, C. L. (2026) · npj Drug Discovery. · doi:10.1038/s44386-026-00074-1 · Cited by 1 · see citing works

4D bioprinting in advanced cancer model: technologies, drug delivery, and translational challenges

Nayak, S., Mohapatra, S., & Kar, R. K. (2026) · Journal of Biomaterials Science Polymer Edition · doi:10.1080/09205063.2026.2733664 · Cited by 1 · see citing works

In vitro 3D microfluidic peritoneal metastatic colorectal cancer model for testing different oxaliplatin-based HIPEC regimens

Canda, A. E., Sever, T., Calibasi‐Kocal, G., Başbınar, Y., & Ellıdokuz, H. (2024) · Pleura and Peritoneum · doi:10.1515/pp-2023-0033 · Cited by 1 · see citing works

Generating evidence on privacy outcomes to inform privacy risk management: A way forward?

Strech, D., Haven, T. L., Madai, V. I., Meurers, T., & Praßer, F. (2022) · Journal of Biomedical Informatics · doi:10.1016/j.jbi.2022.104257

Cancer: A problem of public health in Brazil

Dezena, R. M. B., Gomes, B. H. P., Teixeira, M. B., & Abreu, C. R. D. C. (2023) · Journal of Analytical & Pharmaceutical Research · doi:10.15406/japlr.2023.12.00416

Biomimetic hydrogel supporting baths as an alternative to initiate and maintain breast tumor‐derived organoids culture

Oliveira, J., Pereira, M., Mendes, B. B., & Conde, J. (2023) · MedComm – Biomaterials and Applications · doi:10.1002/mba2.52

Preclinical liver cancer models in the context of immunoprecision therapy: Application and perspectives

Song, F., & Chen, Z. (2023) · World Chinese Journal of Digestology · doi:10.11569/wcjd.v31.i24.989

What does it take to make progress in a disease?Preprint

Ringel, M. S., Dethier, J., Davitt, M. J., Denslow, M., Fowler, R., Hasenfuss, S. C., & Schulze, U. (2024) · medRxiv · doi:10.1101/2024.02.27.24303441

Practice of pediatric oncology drug development

Schrier, L., Pearson, A., Rizzari, C., Huitema, A. D. R., Scobie, N., Reaman, G. H., & Zwaan, C. M. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-88459-4.00021-3

3D Tumor Model to Study Immune Cell Infiltration

Dittmer, J., Pinto, C., Reichel-Voda, C., Souabni, A., Tirapu, I., & Bachmayr-Heyda, A. (2025) · Methods in molecular biology · doi:10.1007/978-1-0716-4418-8_17

Landscape of BRAF transcript variants in human cancer

Podda, M., Tatoni, D., Mattei, G., Magi, A., D’Aurizio, R., & Poliseno, L. (2025) · Molecular Oncology · doi:10.1002/1878-0261.70043

Fast-adapting graph neural network with prior knowledge for drug response prediction across preclinical and clinical data

Guo, H., Lv, X., Li, S., Ma, D.-C., Li, Y.-Z., & Li, M. (2025) · Journal of Pharmaceutical Analysis · doi:10.1016/j.jpha.2025.101386

Prospects of nanotechnology and natural products for cancer and immunotherapy

Santos, J. F. A., Brasileiro, M. B., Barreto, P. D. C., Rocha, L. A., & Júnior, J. A. C. N. (2025) · Beilstein Journal of Nanotechnology · doi:10.3762/bjnano.16.116

The NaaS Methodology applied to modeling chemotherapy-induced peripheral neuropathy with human hiPSC neuronsPreprint

Bessy, T., Lambert, T., Dubuisson, L., Batut, A., Azéma, A., Baquerre, C., Ponomarenko, A., Roux, S., Ftaich, N., & Honegger, T. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.09.25.678500

Genomic variance in Yucatan pigs and detection of donor-derived cell-free DNA after heart transplantation

Mendiola, M., Prinz, J. A., Mitra, K., Lee, F. H., Smith, M. F., Lobo, A. A., Milano, C. A., Bowles, D. E., & Swain-Lenz, D. (2025) · PLoS ONE · doi:10.1371/journal.pone.0334235

A simple circuit to sustain intact tumor microenvironments for complex drug interrogationsPreprint

Sarvestani, A. L., Ruff, S. M., Remmert, K., Teke, M. E., Verbus, E. A., Saif, A., Garmendia‐Cedillos, M., Rossi, A., Rainey, A., Nomie, K. J., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.10.26.684624

Early phase clinical trials in oncology: Realising the potential of seamless designs

Jaki, T., Burdon, A., Chen, X., Mozgunov, P., Zheng, H., & Baird, R. D. (2023) · University of Regensburg Publication Server (University of Regensburg) · doi:10.5283/epub.75717

Discussion of Modeling Techniques, Practical Implications, and Prospective Developments

Ramadurai, K. W., & Banerjee, A. (2026) · SpringerBriefs in bioengineering · doi:10.1007/978-3-032-04012-1_5

Exploring immunoregulatory role of probiotics in cancer-associated cachexia

Mulakhudair, A. R., Shati, Z. R. K., & kh, A. M. (2026) · AIP conference proceedings · doi:10.1063/5.0321872

CBC3T-3: a novel patient-derived cisplatin-resistant distal cholangiocarcinoma cell line harboring multiple TP53 missense mutations

Xi, J., Bai, M., Zhong, R., Huang, C., An, R., Gao, L., Ma, H., Tian, L., Zhao, J., Jiang, N., et al. (2026) · Human Cell · doi:10.1007/s13577-026-01369-1

Quantitative Translational Modeling to Facilitate Preclinical to Clinical Efficacy & Toxicity Translation in Oncology

Zhu, A. (2018) · Future Science OA · doi:10.4155/fsoa-2017-0152 · Cited by 33 · see citing works

Advances in the preclinical testing of cancer therapeutic hypotheses

Caponigro, G., & Sellers, W. R. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3385 · Cited by 165 · see citing works

Translational value of mouse models in oncology drug development

Gould, S. E., Junttila, M. R., & de Sauvage, F. J. (2015) · Nature Medicine · doi:10.1038/nm.3853 · Cited by 293 · see citing works

Preclinical screening models in anticancer drug development: strengths, limitations, and translational challenges

Yadav, R., Singh, S., Kumar, S., Kolay, A., Sharma, H., Dorai, R., Sharma, A. K., Singh, R. P., & Yadav, M. K. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1822764 · Cited by 2 · see citing works

Challenging the status quo to improve the translational potential of preclinical oncology studies

Connor, K., Golebiewska, A., & Byrne, A. T. (2024) · Nature reviews. Cancer · doi:10.1038/s41568-024-00756-w · Cited by 9 · see citing works